Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301038 · ClinicalTrials.gov registry record · Phase 2
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
A Phase 2 study of Genetic Disease and Hypercalciuria, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03301038: Recruiting Phase 2 study of Genetic Disease and Hypercalciuria, sponsored by Children's Hospital of Philadelphia.
NCT03301038 is a Phase 2 study of Genetic Disease and Hypercalciuria that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 60 participants, below the 2,559-participant average among 30 other Genetic Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03301038, a Phase 2 study of Genetic Disease and Hypercalciuria, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
Primary Outcome
Measured at baseline and every 4 weeks
Conditions Studied
Interventions
- DRUG Rifampin
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What NCT03301038 shows while recruiting
NCT03301038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,559-participant average among 30 other Genetic Disease trials with a reported enrollment target (98% lower).
The record links to 6 conditions, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which Rifampin is the first listed.
NCT03301038 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03301038 about?
NCT03301038 is a clinical study titled "Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria". This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
What is the current status of trial NCT03301038?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2018-07-25. Estimated completion is 2030-12.
What conditions does trial NCT03301038 study?
This clinical trial studies the following conditions: Genetic Disease, Hypercalciuria, Idiopathic Infantile Hypercalcaemia - Severe Form, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia.
What interventions are being tested in trial NCT03301038?
The interventions under investigation include: Rifampin (DRUG).
Who is sponsoring clinical trial NCT03301038?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03301038 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03301038's enrollment target sits among peer trials
60 24th of 30 higher than 7 of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
-
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI